AI reads endoscopy images to spot dangerous esophageal tumors
NCT ID NCT07605663
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether artificial intelligence can accurately determine the depth of early esophageal cancer from endoscopic images. Researchers will review past records and images from 890 patients who had their tumors removed. The goal is to see if AI can help doctors decide who needs additional surgery after the initial procedure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
890 people
The number who actually took part.
- Started
-
Jan 2020
- Expected to finish
-
Jun 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Consecutive patients diagnosed with esophageal neoplasms and treated with endoscopic submucosal dissection (ESD) at 2 hospitals, the Endoscopy Center and Endoscopy Research Institute, Zhongshan Hospital (Shanghai and Xiamen), between the January, 2020 and January, 2026 were prospectively enrolled in this study.
- Ages
-
40 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Pathologically confirmed EEC or high-grade intraepithelial neoplasia; * Underwent ESD with complete postoperative pathological report; * Preoperative high-quality WLI, NBl, iodine staining and BLI endoscopic images; * complete clinical data. Exclusion Criteria: * Poor-quality endoscopic images; * Previous esophageal surgery, neoadjuvant chemoradiotherapy, or other malignant tumors; * Missing pathological invasion depth data; * Synchronous distant metastasis.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Esophageal squamous cell carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhongshan Hospital
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Antibody-Drug conjugate targets advanced esophageal cancer after standard treatments fail
- Can a drug combo stop esophageal cancer from returning after surgery?
- Experimental drug put to the test against Hard-to-Treat GI cancers
- Can a drug combo shrink esophageal tumors before surgery?
- Two-Drug combo targets esophageal cancer that outsmarted immunotherapy
- Can a Triple-Drug combo shrink esophageal tumors before surgery?